GLP1R and acute kidney injury: Compared with other hypoglycaemic agents, a recent network meta-analysis suggested that SGLT-2i and GLP-1 receptor agonists, when added to other hypoglycaemic regimens, significantly reduce mortality, non-fatal myocardial infarction, renal failure, and severe hyperglycaemia [63].